A COVID-19 nanoparticle vaccine: cost-effective and accessible

Scientists are currently developing a COVID-19 nanoparticle vaccine that only requires a single dose without the need for strict transport and storage conditions, unlike current approved and available COVID-19 vaccines.

The COVID-19 pandemic has seen over 63 million confirmed cases and over 1 million deaths globally. Ever since the start of the pandemic, the development of a safe and effective vaccine against SARS-CoV-2 – the coronavirus responsible for COVID-19 – has been the priority of public health and researchers worldwide. For scientists at a lab at Stanford University in the United States, biochemist Peter S. Kim and his team redirected efforts from working on vaccines for Ebola, HIV and influenza to developing a vaccine for SARS-CoV-2. They have since been able to design and begin testing a promising new COVID-19 nanoparticle vaccine candidate. The details of their COVID-19 nanoparticle vaccine and its potential are published in ACS Central Science.

The COVID-19 nanoparticle vaccine is still in its early stages and the team is continuously working on improving their vaccine candidate as a single-dose vaccine that can be stored at room temperature. They’re hopeful that advancements in their COVID-19 nanoparticle vaccine will eventually lead to initial clinical trials in humans. Since several other vaccine candidates are currently further in their development and testing phases, the team is also prepared to redirect work efforts again to design a vaccine that can be more broadly used to protect against a wide range of coronaviruses, including the already known SARS-CoV-1, MERS, and SAR-CoV-2 viruses.

Written by Maggie Leung, PharmD.


Image by  from

Keep Reading